XBiotech (NASDAQ:XBIT) Shares Pass Above Fifty Day Moving Average of $6.63

XBiotech Inc. (NASDAQ:XBIT) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $6.63 and traded as high as $7.93. XBiotech shares last traded at $6.79, with a volume of 289,689 shares traded.

XBiotech Trading Down 14.6 %

The company has a market cap of $206.81 million, a PE ratio of -6.66 and a beta of 1.41. The firm has a 50 day moving average of $6.63 and a two-hundred day moving average of $7.11.

XBiotech (NASDAQ:XBIT) last released its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.43) EPS for the quarter.

Institutional Trading of XBiotech

Institutional investors and hedge funds have recently bought and sold shares of the company. Empowered Funds LLC grew its holdings in shares of XBiotech by 7.9% during the first quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 4,725 shares during the last quarter. Vanguard Group Inc. boosted its stake in XBiotech by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company’s stock valued at $7,279,000 after purchasing an additional 13,804 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in XBiotech by 102.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 49,863 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of XBiotech by 2,568.5% in the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 19,341 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of XBiotech in the second quarter worth $393,000. 55.70% of the stock is currently owned by institutional investors.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.